

12

EUROPEAN PATENT APPLICATION

21 Application number: 85108034.1

22 Date of filing: 28.06.85

51 Int. Cl.⁴: C 07 D 401/12
 A 61 K 31/44

30 Priority: 05.07.84 GB 8417171

43 Date of publication of application:
 15.01.86 Bulletin 86/3

84 Designated Contracting States:
 BE CH DE FR GB IT LI NL

71 Applicant: BEECHAM GROUP PLC
 Beecham House Great West Road
 Brentford Middlesex TW8 9BD(GB)

72 Inventor: King, Francis David
 8 Heath Row Bishop's Stortford
 Hertfordshire(GB)

72 Inventor: Burrell, Gordon
 25 Church Lays Harlow
 Essex CM18 6BY(GB)


72 Inventor: Baker, Karen
 16 The Maples Harlow
 Essex CM19 4QY(GB)

74 Representative: Jones, Pauline et al,
 Beecham Pharmaceuticals Patents & Trade Marks Dept.
 Great Burgh Yew Tree Bottom Road
 Epsom Surrey KT18 5XQ(GB)

64 Benzimidazole derivatives, process for their preparation, and their use as pharmaceuticals.

67 Compounds of formula (I):

Inhibiting activity, a process for their preparation and their use as pharmaceuticals.



or a pharmaceutically acceptable salt, a quaternised derivative or a pharmaceutically acceptable solvent thereof; wherein

Y forms an optionally substitute phenyl ring;

n is zero or one;

R₁ is H, C₁₋₆ alkanoyl, C₁₋₆ alkanesulphonyl, or optionally substituted arylsulphonyl, aryl C₁₋₆ alkanoyl or aryl C₁₋₄ alkyl;

R is hydrogen or C₁₋₄ alkyl; and

R₂ is pyridyl group substituted by at least one group selected from OR₄ or O(CH₂)_mOR₄ wherein R₄ is an optionally substituted aryl or alkyl group of up to 10 carbon atoms and m is an integer of from 1 to 4; and by up to three further substituents one of which may be joined to R₂ to form a carbocyclic ring of up to 7 ring atoms having gastric secretion

TITLE MODIFIED
see front page


NOVEL COMPOUNDS

This invention relates to novel compounds, to pharmaceutical compositions containing them, to a process for their preparation and to their use.

The compounds of the invention inhibit gastric secretion and inhibit the enzyme $(H^+ + K^+) - ATPase$, and thus may be used in the treatment of disorders caused or exacerbated by excess gastric acid secretion such as peptic ulcer and Zollinger-Ellison syndrome.

European Patent Application Nos. 007434 and 0005129 disclose various alkoxy substituted pyridylthiobenzimidazoles and alkoxy substituted pyridylsulphonylbenzimidazoles having gastric acid secretion inhibiting activity.

Accordingly, the present invention provides a compound of formula (I):



or a pharmaceutically acceptable salt, a quaternised derivative or a pharmaceutically acceptable solvent thereof;

where in:

Y forms an optionally substituted phenyl ring;

n is zero or one;

R₁ is H, C₁-6 alkanoyl, C₁-6 alkanesulphonyl, or optionally substituted arylsulphonyl, aryl C₁-6 alkanoyl or aryl C₁-4 alkyl;

R₂ is hydrogen or C₁-4 alkyl; and

R₃ is pyridyl group substituted by at least one group selected from OR₄ or O(CH₂)_mOR₄ wherein R₄ is an optionally substituted aryl or aralkyl group of up to 10 carbon atoms and m is an integer of from 1 to 4; and by up to three further substituents one of which may be joined to R₂ to form a carbocyclic ring of up to 7 ring atoms.

Favourably R₃ is an optionally substituted 2-pyridyl group.

Suitable further substituents for R₃ include halogen, C₁-6 alkyl, C₁-6 alkoxy, C₁-6 alkylthio, C₁-6 alkoxy C₁-6 alkoxy, carboxy esterified carboxy, or amino optionally N-substituted by one or two groups independently selected from C₁-6 alkyl, phenyl or phenyl C₁-4 alkyl or optionally N,N-disubstituted by C₄-5 polymethylene or C₃-4 polymethylenecarbonyl.

As used herein the term 'aralkyl' includes aryl C₁-4 alkyl such as phenyl C₁-4 alkyl and naphthyl C₁-4 alkyl and heteroaryl C₁-4 alkyl such as furyl C₁-4 alkyl.

As used herein the term 'aryl' includes phenyl and naphthyl. Suitable example of an arylsulphonyl group for R₁ is benzenesulphonyl and a suitable aryl C₁-6 alkanoyl group is benzoyl.

- 3 -


Any aryl groups may be optionally substituted by one or two substituents selected from halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy and CF₃.

Any optional substituents for R₁ are usually present on the aryl ring. These optional substituents suitably consist of one or two members selected from the group consisting of C₁₋₄ alkyl optionally substituted by halogen, such as trifluoromethyl, C₁₋₄ alkoxy, halogen, nitro, C₁₋₆ alkoxycarbonyl and carboxyl.

Usually R₄ is substituted in the aryl ring portion thereof. Suitable optional substituents are one or two members selected from the group consisting of halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, cyano or nitro. A particularly preferred R₄ is phenyl para-substituted by halo, such as chloro or fluoro.

Favourably the group Y includes one or two substituents selected from halo, C₁₋₆ alkyl, halo substituted C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₁₀ carboxylic acyl, (such as C₁₋₇ alkanoyl and C₃₋₈ alkyl carbonyl), C₁₋₇ carboxylic acylamino, carboxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulphonylamino, N-(C₁₋₆ alkylsulphonyl)-C₁₋₄ alkylamino, cyano, nitro, or amino, amido or sulphonylamino any of which is optionally N-substituted by one or two groups selected from C₁₋₆ alkyl or phenyl or optionally N-disubstituted by C₄₋₅ polymethylene; or phenyl optionally substituted by one or two substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₇ carboxylic acyl, C₁₋₇ carboxylic acylamino, C₁₋₆ alkylsulphonylamino, N-(C₁₋₆ alkylsulphonyl)-C₁₋₄ alkylamino, cyano, or nitro, amino optionally N-substituted by one or two groups selected from C₁₋₆ alkyl or phenyl or optionally N-disubstituted by C₄₋₅ polymethylene, or carboxy or C₁₋₆ alkoxycarbonyl.

A group of compounds within formula (I) is of formula (II):



or a pharmaceutically acceptable salt, a quaternised derivative or a pharmaceutically acceptable solvate thereof;

wherein R_1 , R_2 and n are as hereinbefore defined in relation to formula (I);

R_5 and R_6 are independently hydrogen or a group selected from the substituents for Y defined above;

R_8 is a group selected from OR_4 or $-O(CH_2)_m-O-R_4$;

R_9 and R_{10} are independently selected from hydrogen, $-OR_4$, $-O(CH_2)_mR_4$, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkoxy, carboxy, esterified carboxy, or amino optionally substituted by one or two groups independently selected from C_{1-6} alkyl-phenyl, or phenyl- C_{1-4} alkyl or optionally N,N-disubstituted by C_{4-5} polymethylene or C_{3-4} polymethylenecarbonyl; and R_7 is a group defined above for R_{10} and R_9 or together with R_2 form C_{2-9} alkylene; wherein R_4 and m are as hereinbefore defined in relation to formula (I).

Examples of R_5 and R_6 include hydrogen, halo, such as chloro or bromo, methyl, trifluoromethyl, amino or m thoxy.

R_1 is preferably hydrogen.

Examples of R_2 include hydrogen.

Examples of R_7 , R_9 and R_{10} include hydrogen and C_{1-4} alkyl such as methyl.

Examples of R_8 include phenyl C_{1-4} alkoxy, optionally substituted as hereinbefore defined, in particular benzyloxy.

In one particular embodiment R_7 is methyl, R_8 is benzyloxy or 4-fluorobenzyloxy and R_9 and R_{10} are both hydrogen.

It will be appreciated that the compounds of formulae (I) or (II) may be capable of existing in more than one tautomeric form when $R_1 = H$. The present invention extends to each of these forms and to mixtures thereof.

It will of course be realised that the compounds of the formulae (I) or (II) may have chiral centres, and thus be capable of existing in a number of stereoisomeric forms. The invention extends to each of these stereoisomeric forms (including enantiomers) and to mixtures thereof (including racemates).

An example of a chiral centre is the carbon atom of the moiety $-CHR_2-$ when R_2 is other than hydrogen.

Pharmaceutically acceptable salts of the compounds of the formulae (I) and (II) include pharmaceutically acceptable inorganic salts such as sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide, and pharmaceutically acceptable organic acid additions salts such as acetate, fumarate, tartrate, citrate, lactate, salicylate, malate, succinate, benzoate, ascorbate, methanesulphonate, mandelate, α -ketoglutarate, α -glycerophosphate, and

the acid addition salt is the hydrochloride salt.

Examples of quaternised derivatives include compounds of the formula (I) and (II) quaternised by $R_{18}Q$, where R_{18} is C_1-4 alkyl, C_3-6 cycloalkyl, C_3-6 cycloalkyl, C_1-4 alkyl or phenyl C_1-4 alkyl and Q is halide such as chloride, bromide or iodide.

A particular compound of the formulae (I) or (II) or its acid addition salt can form salts with alkali and alkaline earth metals, usually sodium and potassium, and ammonium and substituted ammonium salts.

Compounds of formula (I) or (II) and their pharmaceutically acceptable salts or quaternised derivatives may form solvates with pharmaceutically acceptable solvents and the invention extends to such solvates.

Crystalline compounds and salts are favoured.


The invention also provides a process for the preparation of a compound of the formula (I) or a pharmaceutically acceptable salt, a quaternised derivative or a pharmaceutically acceptable solvate thereof, which process comprises reacting a compound of formula (III) or an acid addition salt thereof:



(III)

- 7 -

wherein R_3 is as her inb fore defined in relation to formula (I), with a compound of formula (IV):



wherein R_1 and Y are as hereinbefore defined in relation to formula (I); and

- a) R_{11} is a group displaceable by a nucleophile; and R_{12} is CH_3SO ;
- b) R_{11} is CHR_2Q_1 where R_2 is as hereinbefore defined, and Q_1 is a group displaceable by a nucleophile; and R_{12} is HS ; or
- c) R_{11} is CHR_2SH where R_2 is as hereinbefore defined; and R_{12} is a group displaceable by a nucleophile;

thereafter if desired carrying out one or more of the following steps;

- (i) oxidising a compound of formula (I) wherein n is zero to a compound of formula (I) wherein n is one;
- (ii) converting any variable group to another corresponding variable R group; and

(iii) salifying or quaternising the resulting compound of the formula (I).

Suitable examples of R_{11} in variant a) above include halide such as Cl or Br.

Suitable examples of Q_1 and R_{12} in process variants b) and c) respectively include halide such as Cl, Br or I, and labile acyloxy such as OSO_2CH_3 or $OSO_2p-C_6H_4CH_3$ (mesyloxy and tosyloxy).

Reaction in all variants is generally effected at a non-extreme temperature, such as a moderately elevated temperature for example solvent reflux temperature, such as 50 to 150°C, for example 75 to 100°C, in an inert solvent, preferably in the presence of an acid acceptor. The acceptor is suitably an inorganic acid acceptor, such as a strong base for example sodium hydride, butyl lithium or lithium diisopropylamide; a moderately strong base, for example sodium hydroxide; or a moderate base for example calcium carbonate, sodium carbonate or potassium carbonate. In some cases the moderate base acid acceptor is favourably an organic base such as a tertiary amine, e.g. triethylamine, trimethylamine, pyridine or picoline. The most suitable acceptor depends on the particular variant.

Thus for example, for variant a) a strong base is appropriate. For variant b) or c) a moderately strong base or moderate base is appropriate.

The inert solvent can be any solvent inert to both reactants and appropriate to the leaving group, the acid acceptor and desired reaction temperature. Suitable solvents include low molecular weight alkanols such as ethanol, dioxane, dimethylformamide (DMF) toluene, diethyl ether, or methylene chloride.

For process variant b) in particular suitable solvents include polar solvents such as DMF or ethanol. Where reaction is effected in the presence of a base which is insoluble in the polar solvent, water may be added to the solvent. Reaction is generally effected at moderately elevated temperatures as mentioned hereinbefore, such as reaction mixture reflux temperature or at about 100°C, if lower.

It will be appreciated that when the compound of formula (III) or (IV) contains an unsubstituted amino group, such a group will generally be protected, during at least the main reaction of the invention by a conventional N-protecting group for examples an acyl group such as acetyl or phthalyl. Protection may be effected by reaction with an acylating agent such as the relevant acyl chloride or anhydride. Deprotection may be effected for example by base hydrolysis of an acetyl protecting group or treatment of a phthalimide protecting group with hydrazine hydrate in a lower alkanol.

Process variants b) and c) produce compounds of formula (I) wherein n is 0. If a compound of formula (I) is desired wherein n is, it is necessary to oxidise the compound resulting from the process.

Subsequent oxidation may be carried out at below ambient temperatures in a non-aqueous solvent, such as a chlorinated hydrocarbon, in the presence of an organic peracid, such as 3-chloroperbenzoic acid, or in water in the presence of a soluble strong inorganic oxidant, such as aqueous hydrogen peroxide. It will be realised that this process may also N-oxidise any tertiary amino moiety and suitable precautions will

01
02 routinely be taken by the skilled man, if it is desired
03 to avoid this.

04
05 The conversions in step (iii) above are carried out by
06 conventional methods.

07
08 Examples of such conversions include the conversion of
09 Y group substituent to another. In particular

- 10
11 a) hydrogen is convertible to a nitro substituent by
12 nitration;
13
14 b) a nitro substituent is convertible to an amino
15 substituent by reduction;
16
17 c) an acylamino substituent is convertible to an
18 amino substituent by deacylation;
19
20 d) an amino substituent is convertible to acylamino
21 substituent by acylation;
22
23 e) hydrogen is convertible to a halo substituent by
24 halogenation;
25
26 f) a fluoro or chloro substituent is convertible to
27 an optionally substituted amino substituent by
28 reaction with suitable amine or ammonia;
29
30 g) an amino substituent is convertible to a halo,
31 cyano, or hydrogen substituent by diazotisation
32 and simultaneous nitrogen elimination with
33 halogenation, cyanation, or reduction;
34
35 h) an amino substituent is convertible to an
36 alkylated amino substituent by alkylation or
37 reductive alkylation; and

- i) a carboxy substituent is convertible to a C₁₋₆ alkoxycarbonyl substituent by esterification.

In regard to (a), nitration is carried out in accordance with known procedures.

In regard to (b), the reduction is carried out using methods conventional for reducing nitro groups on aromatic nuclei, for example using Raney nickel, stannous chloride or iron powder in glacial acetic acid or hydrochloric acid.

In regard to (c), deacylation is carried out by treatment with a base, such as an alkali metal hydroxide.

In regard to (d), the acylation is carried out with an acylating agent, such as the corresponding acid anhydride or acid chloride. Formylation is carried out with formic acid.

In regard to (e), halogenation is carried out with conventional halogenating agents, under conventional reaction conditions for the halogenation of aromatic nuclei, that is with the relevant halogen in the presence of a Lewis acid catalyst, such as ferric chloride, zinc chloride or boron trifluoride, in an inert organic solvent such as chloroform or dichloromethane, at temperatures below ambient. Alternatively a polar solvent, such as glacial acetic acid without a catalyst may be used.

In regard to (f), the amination is carried out under conventional conditions using an inert solvent such as ethanol or an excess of amine also functioning as the solvent.

(g) may be effected by reacting an alkali metal nitrite, a strong inorganic acid and the reaction product in aqueous solution at 10 to -10°C.

Subsequent simultaneous nitrogen elimination and halogenation, cyanation or reduction may be effected by treating the diazotisation product with a halide, cyanide or hydride source, under either Sandmeyer or Schiemann reaction conditions for halide and nitrile, or by treatment with hypophosphorous acid for hydride respectively.

(h) and (i) may be effected entirely conventionally.

For R₃;

- j) H may be converted to acyl by conventional acylation.
- k) any of the acyl groups listed hereinbefore for R₁₁ may be converted to hydrogen by conventional deacylation.
- l) carboxy may be converted to C₁₋₆ alkoxy carbonyl by conventional esterification.

In regard to (j) O-acylation is carried out under conventional conditions with an acylating agent which has an acyl group capable of forming an hydrolysable acyloxy group and a leaving group, such as halide, for example chloride and bromide, and hydrogen. When halide is the leaving group, the reaction is generally carried out in the presence of a base. When hydroxy is the leaving group, the reaction is generally carried out in the presence of a dehydrating agent, at a non-extreme temperature, such as ambient temperature.

In regard to (k), deacylation is carried out by treatment with a base, such as an alkali metal hydroxide.

In regard to (l) esterification is entirely conventional.

Conversions (a) to (l) are only exemplary and are not exhaustive of the possibilities.

In general, interconversion of R₇, R₈, R₉ and R₁₀ to other R₇, R₈, R₉ and R₁₀ will not be readily effected. However, such interconversions as are possible, and suitable methods and conditions for effecting them, will be readily apparent to the skilled man.


The choice or necessity of variable interconversion will be dictated by the nature and position of the variable, as will the choice of intermediate or compound in which interconversion is effected.

In all the foregoing interconversions, the effect, if any, on other substituents should be considered, and such reagents as are appropriate should be selected together with the adoption of such routine precautionary measures as are necessary.

It is however preferred that any conversions are carried out at the earliest stage possible in the synthesis.

The invention also provides a process, for the preparation of a compound of formula (I) as hereinbefore defined or a pharmaceutically acceptable

salt or quaternary derivative thereof, which process comprises reacting a compound of formula (V) or a pharmaceutically acceptable salt thereof:



wherein

R_1 , R_2 , Y and n are as defined in relation to formula (I) and R_3' is a pyridyl group substituted by at least one hydroxy or C_1 -4 alkoxy groups and up to three further substituents independently selected from halogen, C_1 -6 alkyl, C_1 -6 alkoxy, C_1 -6 alkylthio, C_1 -6-alkoxy C_1 -6 alkoxy, carboxy esterified carboxy, or amino optionally N -substituted by one or two groups independently selected from C_1 -6 alkyl, phenyl or phenyl C_1 -4 alkyl or optionally N,N -disubstituted by C_4 -5 polymethylene or C_3 -4 polymethylenecarbonyl, or one of said further substituents is joined to R^2 to form a carbocyclic ring of up to 7 ring atoms; with a compound of formula $R_{13}Q_2$;

wherein:

R_{13} is R_4 as hereinbefore defined or when R_3' is substituted by hydroxy, R_{13} can be $(CH_2)_mOR_4$ and Q_2 is a leaving group; in which m is as hereinbefore defined; and thereafter if necessary, carrying out one or more of the following steps:

- (i) oxidising a compound of formula (I) wherein n is zero to a compound of formula (I) wherein n is one;

(ii) converting any variable R group to another corresponding variable R group; and

(iii) salifying or quaternising the resulting compound of the formula (I).

Suitable examples of Q₂ include halide such as Chloro or bromo.

Process conditions may be conventional conditions for the alkylation of an aromatic hydroxy substituent.

The interconversion of variables groups may be effected as described hereinbefore.

In the above described processes, compounds of the formula (I) may be salified in entirely conventional manner by reacting a compound of the formula (I) in base form with a chosen acid to form acid addition salts.

The quaternary derivatives of the compounds of the formula (I) may be prepared in conventional manner, such as by reaction of the chosen compound of the formula (I) with a compound R₁₈Q as defined. This reaction is suitably carried out in an appropriate solvent such as acetone, methanol or ethanol.

Salts of compounds of the formula (I) containing a carboxy groups may be formed conventionally by reacting a compound of the formula (I) with a corresponding base, for example an alkali metal hydroxide, an alkaline earth metal hydroxide or an optionally substituted ammonium hydroxide.

01
02 Th preparation of intermediates for the preparative
03 process of the invention may be effected by building up
04 the intermediates in any given process or process
05 variant by processes analogous to those in other
06 relevant variants of the first process of the invention
07 or by conventional oxidation as described
08 hereinbefore for a compound of the formula (I), or such
09 intermediates are known compounds or are preparable
10 analogously to or routinely derivable from known
11 compounds.

12
13 The intermediates of formula (III) in all the variants
14 of the first process are known compounds, or are
15 preparable analogously to, or are routinely derivable
16 from known compounds.

17
18 For example the intermediates of formula (III) in
19 variant a) of the first process of the invention, i.e.
20 wherein R_{10} is a group displaceable by a nucleophile,
21 in particular chloro or bromo, may be prepared by
22 halogenation of the corresponding 2-pyridone. Suitable
23 halogenating agents include phosphorus oxychloride,
24 phosphorus oxybromide, thionyl chloride, and phosphorus
25 pentachloride used under conventional conditions for
26 each given reagent.

27
28 It is believed that the intermediates of formula (IV)
29 in all the variants of the first process are known
30 compounds or are preparable analogously to, or are
31 routinely derivable from known compounds.

32
33 However, by way of example the preparation of various
34 intermediates of formula (IV) are described
35 hereinafter:
36

In variant (a) of the first process, the intermediates of formula (IV), i.e. wherein R_{11} is CH_3SO may be prepared by oxidising in the manner described hereinbefore for a compound of formula (I), a corresponding compound wherein the CH_3SO group is replaced by CH_3S . This compound may be prepared by conventional S-alkylation of a compound of formula (V) wherein R_{11} is SH , i.e. the intermediate of process variant (b).

In process variant (b), the intermediate of formula (IV), i.e. wherein R_{11} is HS may be prepared by reacting a compound of formula (V) wherein R_{11} is a group displaceable by a nucleophile with thiourea followed by base hydrolysis of the thiuronium salt.

The intermediates of formula (V) are believed to be novel and as such form an aspect of the present invention.

They are preparable by a process analogous to the first process of this invention. The skilled man will appreciate that in such a process it is desirable to protect any R_7 hydroxy group to prevent electrophilic attack on the group oxygen atom. Protection may be achieved for example using a C_{1-6} alkyl group, which may be conventionally converted to hydrogen subsequent to the main reaction, for example using warm hydrobromic acid or iodotrimethylsilane.

The compounds of formulae (I) and (II), pharmaceutically acceptable salts and quaternised derivatives thereof, and pharmaceutically acceptable solvates of any of the foregoing may be used in the treatment of disorders caused or exacerbated by excess gastric acid secretion such as peptic ulcer and Zollinger-Ellison syndrome.

The invention thus also provides a pharmaceutical composition comprising a compound of the invention, in particular a compound of formula (I), a pharmaceutically acceptable salt, quaternised derivative or a pharmaceutically acceptable solvate thereof, together with a pharmaceutically acceptable carrier.

The compositions may be formulated for administration by any route, although oral administration is preferred. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutible powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.

Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.

The solid oral compositions may be prepared by conventional methods of blending, filling, or tableting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in

the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

When appropriate the compositions of this invention may be presented as an aerosol for oral administration, as a microfine powder for insufflation, or as a suppository for rectal or vaginal administration. Suitable unit dose forms include tablets, capsules and powders in sachets or vials, and preferred forms include shaped oral unit doses, such as tablets and capsules.

The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration.

The invention also provides a method of treatment or prophylaxis of disorders, such as peptic ulcers, in mammals including humans, caused or exacerbated by excess gastric acid secretion, which comprises the administration of an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or quaternised derivative thereof, or a pharmaceutically acceptable solvate of any of the foregoing, to the sufferer.

An amount effective to treat the disorders hereinbefore described depends on the relative efficacies of the compounds of the invention, the nature and severity of the disorder being treated and the weight of the mammal. However, a unit dose will normally contain 1 to 2000 for example 5 to 1000 mg of the compound of the invention. Unit doses will normally be administered at least once a day, for example 1,2,3,4,5 or 6 times a day such that the total daily dose is normally in the range 0.1 to 30 mg/kg per day, i.e. 7 to 2000 mg/day for a 70kg human adult.


As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

The invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a quaternised derivative or a pharmaceutically acceptable solvate thereof for use in therapy, in particular for use in the treatment or prophylaxis of disorders caused or exacerbated by excess gastric acid secretion.

The following Examples illustrate the preparation of active compounds of the formula (I). The following Descriptions illustrate the preparation of intermediates thereto.

All temperatures are in degrees Celsius.

The following Pharmacological Data Section illustrates the useful activity of the compounds.

Description 14-Chloro-2,3-dimethylpyridine-1-oxide (D1)

D.1

2,3-Dimethyl-4-nitropyridine-1-oxide (1.3g) was added portionwise to acetyl chloride (6ml) at 0°C. The mixture was allowed to warm to room temperature for 7 minutes before pouring onto crushed ice. The solution was made alkaline (pH 9) with potassium carbonate and extrated with chloroform (2 x 30ml). The combined organic phase was washed with brine (50ml) and dried (MgSO₄). Evaporation of the solvent gave a yellow oil (1.13g) which was purified by column chromatography (Silica gel - Merck 7734) eluting with chloroform - 5% methanol:95% chloroform to give 4-chloro-2,3-dimethylpyridine-1-oxide (0.94g) as a pale yellow solid (77%).


¹H-NMR (CDCl₃/CCl₄)

δ = 2.4 (s, 3H)

δ = 2.5 (s, 3H)

δ = 7.1 (d, 1H)

δ = 8.0 (d, 1H)

Description 2(4-Benzyloxy-3-methylpyrid-2-yl)methyl acetate (D2)


D.2

4-Chloro-2,3-dimethylpyridine-1-oxide (3,4g; 22mmol) was added to a mixture of potassium t-butoxide (2.9g, 24.2mmol) in benzylalcohol (15ml). The mixture was heated to 100°C for 72hrs followed by evaporation of most of the benzyl alcohol under high vacuum. The residue was partitioned between water (100ml) and chloroform (100ml). The organic phase was washed with brine (70ml), dried (MgSO₄) and evaporated in vacuo. The residue was then heated under high vacuum to remove residual benzyl alcohol.

A solution of the crude 4-benzyloxy-2,3-dimethylpyridine-1-oxide thus obtained, in acetic anhydride (23ml), was heated on a steam bath for 1 hour. Evaporation of the solvent left a brown gum which was triturated under xylene and then evaporated in vacuo. The residue was partitioned between chloroform (150ml) and dilute sodium bicarbonate solution (150ml). The organic phase was washed with brine (70ml) dried (Na₂SO₄) and concentrated in vacuo to give a black oil. Column chromatography (silica gel - Merck 7734), eluting with ethyl acetate, gave the (4-benzyloxy-3-methylpyrid-2-yl)methyl acetate as a pale brown oil (3.81g) (65%).

¹H-NMR (CCl₄)


δ = 2.0 (s, 3H)	δ = 6.6 (d, 1H)
δ = 2.2 (s, 3H)	δ = 7.3 (s, 5H)
δ = 5.0 (s, 2H)	δ = 8.1 (d, 1H)
δ = 5.1 (s, 2H)	

Description 34-Benzyloxy-3-methylpyridine-2-methanol (D3)

A solution of (4-benzyloxy-3-methylpyrid-2-yl)methyl acetate (3.81g, 14mmol) and 10% sodium hydroxide solution (14.1ml) in ethanol (50ml) was heated on a steam bath for 30 minutes. The solvent was evaporated in vacuo, and the residue partitioned between chloroform (100ml) and water (100ml). The organic phase was washed with brine (75ml), dried (Na₂SO₄) and evaporated in vacuo to give the 4-benzyloxy-3-methylpyridine-2-methanol (3.17g) as a yellow solid (98%).

¹H-NMR (CDCl₃/CCl₄)


δ = 2.1 (s, 3H)
δ = 4.6 (brs, 3H)
δ = 5.1 (s, 2H)
δ = 6.7 (d, 1H)
δ = 7.3 (s, 5H)
δ = 8.2 (brm, 1H)

Description 44-Benzyloxy-2-chloromethyl-3-methylpyridine
hydrochloride (D4)

Thionyl chloride (0.6ml, 8mmol) was added to a solution of 4-benzyloxy-3-methyl-pyridine-2-methanol (460mg, 2mmol) in chloroform (10ml) at room temperature. The solution was then heated under reflux for 30 minutes. After cooling the solvent was evaporated in vacuo, triturated under xylene and re-evaporated in vacuo. The residue was triturated under ether to yield the 4-benzyloxy-2-chloromethyl-3-methylpyridine hydrochloride (0.57g) as an off-white solid (mp 160-1°C).

¹H-NMR (CDCl₃ + d⁶-DMSO)

δ = 2.4 (s, 3H)
δ = 5.0 (s, 2H)
δ = 5.3 (s, 2H)
δ = 7.1-7.7 (m, 7H)
δ = 8.4 (d, 1H)

Example 1a2-[(4-Benzyloxy-3-methylpyrid-2-yl)methylthio]benzimidazole (E1a)

A solution of 4-benzyloxy-2-chloromethyl-3-methylpyridine hydrochloride (0.57g, 2mmol) in ethanol (20ml) was added to a solution of 2-mercaptobenzimidazole (0.316g, 2.1mmol) and 10% sodium hydroxide solution (1.6ml, 4mmol) in ethanol (20ml). The solution was allowed to stand overnight. Solvent was evaporated in vacuo and the residue partitioned between chloroform (25ml) and water (25ml) and the aqueous phase was further extracted with chloroform (25ml). The combined organic extracts were washed with brine (35ml), dried (Na₂SO₄) and evaporated in vacuo to give an oily solid (0.78g). Recrystallisation from ethyl acetate gave 2-[(4-benzyloxy-3-methylpyrid-2-yl)methylthio]benzimidazole (0.58g) as a white solid (80%) (mp 189-191°C).

¹H-NMR (CDCl₃-d⁴ MeOH-d⁶-DMSO)

δ = 2.3 (s, 3H)

δ = 4.7 (s, 2H)

δ = 5.2 (s, 2H)

δ = 6.9 (d, 1H)

δ = 7.0-7.7 (m, 9H - includes singlet at δ.7.4)

δ = 8.3 (d, 1H)

Similarly prepared were:-

Example 2a:

2-[(4-benzyloxy-3-methylpyrid-2-yl)methylthio]-5-methoxy-benzimidazole (E2a);

$^1\text{H-NMR}$ ($\text{CDCl}_3\text{-d}^4\text{MeOH}$) δ = 2.3(s, 3H); 3.8(s, 3H); 4.4(s, 2H); 5.1(s, 2H); 6.6-7.0(m, 3H); 7.1-7.5(m, 6H); 8.2(d, 1H).

Example 3a:

2-[(4-benzyloxy-3-methylpyrid-2-yl)methylthio]-5-bromo-6-nitro-benzimidazole.

Example 4a:


2-[(4-benzyloxy-3-methylpyrid-2-yl)methylthio]-5-trifluoromethylbenzimidazole;

$^1\text{H-NMR}$ ($\text{CDCl}_3\text{-d}^4\text{-MeOH}$) δ = 2.3(s, 3H); 4.5(s, 2H); 5.1(s, 2H); 6.7(d, 1H); 7.2-7.6(m, 7H); 7.7(s, 1H); 8.2(d, 1H).

Example 5a:

2-[(4-benzyloxy-3-methylpyrid-2-yl)methylthio]-5-methylbenzimidazole;

$^1\text{H-NMR}$ ($\text{CDCl}_3\text{-d}^4\text{-MeOH}$) δ = 2.3(s, 3H); 2.4(s, 3H); 4.4(s, 2H); 5.1(s, 2H); 6.6-7.1(m, 7H); 8.2(d, 1H).

Exempl 6a:5-Amino-6-bromo-2-[(4-benzyloxy-3-methylpyrid-2-yl)-methylthio]-benzimidazole

E.6a

Stannous chloride (0.51g, 2.7mmol) was added portionwise to a solution of 2-[(4-benzyloxy-3-methylpyrid-2-yl)methylthio]-5-bromo-6-nitrobenzimidazole (E3a) (0.327g, 0.7mmol) and 5N hydrochloric acid (1.2ml) in ethanol (30ml). The solution was allowed to stand overnight. The solution was made basic with saturated potassium carbonate (pH 11) and extracted with ethyl acetate (3 x 30ml). The combined organic phase was washed with water (2 x 30ml), brine (50ml) and dried (Na₂SO₄). Evaporation of solvent gave an oily solid. Column chromatography (silica gel, Merck 7734), eluting with chloroform - 5% methanol:95% chloroform, gave the 5-amino-6-bromo-2-[(4-benzyloxy-3-methylpyrid-2-yl)methylthio]-benzimidazole (6a) (0.21g) as a yellow solid (73%).

¹H-NMR (CDCl₃)

δ = 2.2 (s, 3H)

δ = 4.3 (s, 2H)

δ = 5.0 (s, 2H)


δ = 6.6 (d, 1H)

δ = 6.7 (s, 1H)

δ = 7.2 (s, 5H)

δ = 7.5 (s, 1H)

δ = 8.2 (d, 1H)

Example 1b2-[(4-Benzoyloxy-3-methylpyrid-2-yl)methylsulphanyl]-benzimidazole

(El.b)

m-Chloroperoxybenzoic acid (131mg, 76mmol) was added to a stirred solution of 2-[(4-benzyloxy-3-methylpyrid-2-yl)methylthio]benzimidazole (Ela) (250mg, 69mmol) in dichloromethane (30ml) at 0°C under an atmosphere of nitrogen. After 5 minutes dilute sodium bicarbonate solution (30ml) was added and the mixture partitioned. The organic phase was dried (Na₂SO₄) and evaporated in vacuo to give a dark oil. Trituration under acetonitrile (2ml) gave a solid which was filtered, washed with ether and dried in vacuo to give the 2-[(4-benzyloxy-3-methylpyrid-2-yl)methylsulphanyl]-benzimidazole (Elb) (206mg) as a grey solid (mp 139-141°C dec).

¹H-NMR (CDCl₃)

δ = 2.22 (s, 3H)

δ = 4.83 (s, 2H)

δ = 5.09 (s, 2H)

δ = 6.27 (d, 1H)

δ = 7.15-7.8 (m, 10H, includes singlet at δ = 7.42)


δ = 8.33 (d, 1H)

Similarly were prepared:-

Example 2b:


2-[(4-benzyloxy-3-methylpyrid-2-yl)methylsulphonyl]-5-methoxy-benzimidazole (E2b):

¹H-NMR (CD₂Cl₂) δ = 2.15(s, 3H); 3.78(s, 3H); 4.75(s, 2H); 5.06(s, 2H); 6.65-7.1 (m, 3H); 7.2-7.6(m, 6H); 8.27(d, 1H).




Example 7a


2-[(4-[4-Methoxybenzyloxy]-3-methylpyrid-2-yl)methyl-
thio]benzimidazole

Example 8a

2-[(4-[3,5-Dichlorobenzyloxy]-3-methylpyrid-2-yl)methyl-
thio]benzimidazole


Example 9a

2-[(4-[3,5-Dichlorobenzyloxy]-3-methylpyrid-2-yl)methyl-
thio]-5-methylbenzimidazole




Example 10a


2-[(4-[4-Fluorobenzyloxy]-3-methylpyrid-2-yl)methylthio]benzimidazole

Example 11a

2-[(4-Fluorobenzyloxy)-3-methylpyrid-2-yl)methylthio]-5-methylbenzimidazole


Example 12a

5-Chloro-2-[(4-[4-fluorobenzyloxy]-3-methylpyrid-2-yl)-methylthio]benzimidazole




Example 13a


2-[(4-[4-Chlorobenzyloxy]-3-methylpyrid-2-yl)methylthio]benzimidazole

Example 14a

2-[(4-Benzyloxypyrid-2-yl)methylthio]benzimidazole


Example 15a

5-Chloro-2-[(4-[4-chlorobenzyloxy]-3-methylpyrid-2-yl)-methylthio]benzimidazole




Exempl 16a


5-Chloro-2-[(4-[3,5-dichlorobenzyloxy]-3-methylpyrid-2-yl)methylthio]benzimidazole




Example 17a

2-[(4-Benzyloxypyrid-2-yl)methylthio]-5-trifluoromethyl benzimidazole

Example 18a


2-[(4'-Phenethyloxypyrid-2-yl)methylthio]benzimidazole




Example 19a2-[(4-Benzyloxy)pyrid-2-yl)methylthio]-5-chlorobenzimidazoleExample 20a2-[(3-Methyl-4-phenoxy)pyrid-2-yl)methylthio]benzimidazoleExample 21a2-[(4-(4-Fluorobenzyloxy)pyrid-2-yl)methylthio]benzimidazole

Example 22a


2-[(4-[4-Fluorophenoxy]-3-methylpyrid-2-yl)methylthio]-
benzimidazole

Example 23a

2-[1-([4-(4-Fluorobenzoyloxy)pyrid-2-yl]ethyl)thio]-
benzimidazole


Example 24a

2-[(4-Benzoyloxy-5-methylpyrid-2-yl)methylthio]benzimi-
dazole




Example 25a

2-[(4-Benzoyloxy-5-methylpyrid-2-yl)methylthio]-5-methoxybenzimidazole




Example 26a

2-[(4-[4-Chlorobenzoyloxy]-3-methylpyrid-2-yl)methylthio]-5-cyclopropylcarbonylbenzimidazole




Example 27a

2-[(4-Benzoyloxy-5-methylpyrid-2-yl)methylthio]-5-chlorobenzimidazole




Examp1 28a


2-[(4-Benzyloxy-5-methylpyrid-2-yl)methylthio]-5-tri-fluoromethylbenzimidazole

Example 29a

2-[(4-[4-Fluorobenzyloxy]-5-methylpyrid-2-yl)methylthio]benzimidazole


Example 30a


2-[(4-[4-Fluorobenzyloxy]-5-methylpyrid-2-yl)methylthio]-5-methylbenzimidazole




Example 31a

2-[(4-Benzyloxy-5-methylpyrid-2-yl)methylthio]-5-methyl
benzimidazole




Exempl 4b2-[(4-Benzyloxy-3-methylpyrid-2-yl)methylsulphinyl]-5-trifluoromethylbenzimidazole¹H-NMR (CD₂Cl₂)

δ	2.17 (s, 3H)
	4.70 (d, 1H)
	4.71 (d, 1H)
	5.06 (s, 2H)
	6.79 (d, 1H)
	7.38 (s, 5H)
	7.51 (dd, 1H)
	7.69 (d, 1H)
	7.92 (s, 1H)
	8.25 (d, 1H)

Example 5b2-[(4-Benzyloxy-3-methylpyrid-2-yl)methylsulphinyl]-5-methylbenzimidazole

¹H-NMR (CD₂Cl₂)


δ	2.14 (s, 3H)
	2.42 (s, 3H)
	4.57 (d, 1H)
	4.93 (d, 1H)
	5.05 (s, 2H)
	6.79 (d, 1H)
	6.99-7.69 (m, 8H, includes singlet at δ = 7.38)
	8.30 (d, 1H)

Example 6b5-Amino-6-bromo-2-[(4-benzyloxy-3-methylpyrid-2-yl)-methylsulphonyl]-benzimidazole¹H-NMR (CD₂Cl₂ + d⁶-DMSO)

δ	2.19 (s, 3H)
	4.68 (s, 2H)
	4.90 (br.s, 2H)
	5.17 (s, 2H)
	6.92 (d, 1H)
	7.05 (s, 1H)
	7.28-7.55 (m, 5H)
	7.75 (s, 1H)
	8.27 (d, 1H)
	12.95 (br.s, 1H)

Example 7b

2-[(4-[4-methoxybenzyloxy]-3-methylpyrid-2-yl)methylsulphanyl]benzimidazole




¹H-NMR (CD₂Cl₂)

δ	2.14 (s, 3H)
	3.80 (s, 3H)
	4.67 (d, 1H)
	4.87 (d, 1H)
	5.01 (s, 2H)
	6.74-7.04 (m, 3H)
	7.16-7.48 (m, 4H)
	7.48-7.73 (m, 2H)
	8.31 (d, 1H)

Example 8b


2-[(4-[3,5-dichlorobenzyloxy]-3-methylpyrid-2-yl)methylsulphanyl]benzimidazole



Mass spectrum C₂₁H₁₅N₃OSCl₂ required 427.0313
observed 427.0319

Example 9b

2-[(4-[3,5-dichlorobenzyloxy]-3-methylpyrid-2-yl)methylsulphinyl]-5-methylbenzimidazole




¹H-NMR (CD₂Cl₂)

2.19	(s, 3H)
2.45	(s, 3H)
4.60	(d, 1H)
4.85	(d, 1H)
5.03	(s, 2H)
6.75	(d, 1H)
7.00-7.62	(m, 6H)
8.32	(d, 1H)

Example 10b

2-[(4-[4-Fluorobenzyloxy]-3-methylpyrid-2-yl)methylsulphinyl]benzimidazole




¹H-NMR (d⁶DMSO).


δ	2.18 (s, 3H)
	4.68 (d, 1H)
	4.87 (d, 1H)
	5.21 (s, 2H)
	7.00-7.80 (m, 9H)
	8.27 (d, 1H)

Example 11b

2-[(4-[4-Fluorobenzyloxy]-3-methylpyrid-2-yl)methyl-
sulphinyl]-5-methylbenzimidazole

¹H-NMR (CD₂Cl₂)

δ	2.14 (s, 3H)
	2.44 (s, 3H)
	4.66 (d, 1H)
	4.85 (d, 1H)
	5.03 (s, 2H)
	6.79 (d, 1H)
	6.91-7.65 (m, 8H)
	8.30 (d, 1H)

Example 12b5-Chloro-2-[(4-[4-Fluorobenzyloxy]-3-methylpyrid-2-yl)-methylsulphonyl]benzimidazole¹H-NMR (CD₂Cl₂ + d⁶DMSO)

δ 2.21 (s, 3H)


4.72 (s, 2H)

5.14 (s, 2H)

6.89 (d, 1H)


6.78-7.71 (m, 7H)

8.28 (d, 1H)


Example 13b2-[(4-[4-Chlorobenzyloxy]-3-methylpyrid-2-yl)methylsulphonyl]benzimidazole

¹H-NMR (CD₂Cl₂)


δ	2.19 (s, 3H)
	4.47 (d, 1H)
	4.85 (d, 1H)
	5.08 (s, 2H)
	6.81 (d, 1H)
	7.16-7.48 (m, 6H, includes singlet at δ = 7.38)
	7.48-7.80 (m, 2H)
	8.31 (d, 1H)

Example 14b2-[(4-Benzyloxypyrid-2-yl)methylsulphonyl]benzimidazole¹H-NMR (CD₂Cl₂ + d⁶-DMSO)

δ	4.47 (d, 1H)
	4.72 (d, 1H)
	4.85 (s, 2H)
	6.70 (d, 1H)
	6.83 (dd, 1H)
	7.16-7.51 (m, 7H, includes singlet at δ = 7.37)
	7.51-7.84 (m, 2H)
	8.37 (d, 1H)
	12.95 (br.s, 1H)

Example 15b5-Chloro-2-[(4-[4-chlorobenzyloxy]-3-methylpyrid-2-yl)-methylsulphiny]benzimidazole¹H-NMR (CD₂Cl₂)

δ	2.20 (s, 3H)
	4.60 (d, 1H)
	4.85 (d, 1H)
	5.10 (s, 2H)
	6.80 (d, 1H)
	7.29 (dd, 1H)
	7.40 (s, 4H)
	7.59 (d, 1H)
	7.63 (s, 1H)
	8.31 (d, 1H)

Example 16b5-Chloro-2-[(4-[3,5-dichlorobenzyloxy]-3-methylpyrid-2-yl)-methylsulphiny]benzimidazole


- 48 -

 $^1\text{H-NMR}$ ($\text{CD}_2\text{Cl}_2 + \text{d}^6\text{-DMSO}$)


δ	2.22 (s, 3H)
	4.63 (d, 1H)
	4.80 (d, 1H)
	5.13 (s, 2H)
	6.86 (d, 1H)
	7.27 (dd, 1H)
	7.41 (s, 3H)
	7.61 (d, 1H)
	7.68 (s, 1H)
	8.27 (d, 1H)

Example 17b


2-[(4-Benzyloxypyrid-2-yl)methylsulphonyl]-5-trifluoro-
methylbenzimidazole

 $^1\text{H-NMR}$ (CD_2Cl_2)

δ	4.45-4.93 (m, 4H)
	6.61-6.87 (m, 2H)
	7.11-7.46 (m, 5H)
	7.56 (dd, 1H)
	7.76 (d, 1H)
	7.98 (s, 1H)
	8.29 (d, 1H)
	9.62 (br.s, 1H)

Example 18b2-[(4'-Phenethyloxy)pyrid-2-yl)methylsulphiny]benzimidazole¹H-NMR (CD₂Cl₂)

δ	2.91 (t, 2H)
	3.77-4.01 (m, 2H)
	4.48 (d, 1H)
	4.73 (d, 1H)
	6.54-6.77 (m, 2H)
	7.09-7.50 (m, 7H)
	7.50-7.75 (m, 2H)
	8.29 (d, 1H)


Example 19b2-[(4-Benzyloxy)pyrid-2-yl)methylsulphiny]-5-chloro-benzimidazole

¹H-NMR (CD₂Cl₂ + d⁶-DMSO)

δ	4.45 (d, 1H)
	4.70 (d, 1H)
	4.88 (s, 2H)
	6.66-6.90 (m, 2H)
	7.18-7.68 (m, 8H, includes singlet at δ = 7.29)
	8.34 (d, 1H)


Example 20b

2-[(3-Methyl-4-phenoxy-pyrid-2-yl)methylsulphanyl]-
benzimidazole




¹H-NMR (CD₂Cl₂)

δ	2.26 (s, 3H)
	4.72 (d, 1H)
	4.92 (d, 1H)
	6.55 (d, 1H)
	6.83-7.09 (m, 2H)
	7.09-7.46 (m, 5H)
	7.46-7.87 (m, 2H)


Exempl 21b2-[(4-(4-Fluorobenzoyloxy)pyrid-2-yl)methylsulphanyl]-
benzimidazole¹H-NMR (CD₂Cl₂)

δ	4.50-4.77 (m, 4H)
	7.60 (d, 1H)
	7.74 (dd, 1H)
	6.98-7.09 (m, 2H)
	7.16-7.26 (m, 2H)
	7.26-7.35 (m, 2H)
	7.40-7.90 (m, 2H)
	8.25 (d, 1H)
	12.26 (br.s, 1H)


Example 22b2-(4-[4-Fluorophenoxy]-3-methylpyrid-2-yl)methylsul-
phanyl]benzimidazole

¹H-NMR (CD₂Cl₂)


δ	2.25 (s, 3H)
	4.71 (d, 1H)
	4.91 (d, 1H)
	6.52 (d, 1H)
	6.82-7.45 (m, 6H)
	7.45-7.84 (m, 2H)
	8.24 (d, 1H)
	12.3 (br.s, 1H)

Example 23b2-[1-([4-(4-Fluorobenzyloxy)pyrid-2-yl]ethyl)sulphonyl]benzimidazole¹H-NMR (CD₂Cl₂)

δ	1.80 (d, 3H)
	4.20-4.78 (m, 3H)
	6.47 (d, 1H)
	6.65 (d,d, 1H)
	6.73-7.94 (m, 8H)
	8.23 (d, 1H)
	12.05 (br.s, 1H)

Example 24b2-[(4-Benzyloxy-5-methylpyrid-2-yl)methylsulphinyl]-
benzimidazole¹H-NMR (CD₂Cl₂)

δ	2.11 (s, 3H)
	4.34-4.84 (m, 4H)
	6.50 (s, 1H)
	7.13-7.47 (m, 7H)
	7.47-7.77 (m, 2H)
	8.15 (s, 1H)


Example 25b2-[(4-Benzyloxy-5-methylpyrid-2-yl)methylsulphinyl]-5-
methoxybenzimidazole

¹H-NMR (CD₂Cl₂)

δ	2.10 (s, 3H)
	3.80 (s, 3H)
	4.32-4.82 (m, 4H)
	6.48 (s, 1H)
	6.83-7.12 (m, 2H)
	7.12-7.65 (m, 6H)
	8.15 (s, 1H)


Example 26b

2-[(4-[4-Chlorobenzoyloxy]-3-methylpyrid-2-yl)methylsulphanyl]-5-cyclopropylcarbonylbenzimidazole




¹H-NMR (CDCl₃)

δ	8.35 (s, 1H)
	8.30 (d, 1H)
	8.04 (dd, 1H)
	7.64 (d, 1H)
	7.50-7.20 (m, 4H)
	6.75 (d, 1H)
	5.03 (s, 2H)
	4.82 (s, 2H)
	2.90-2.50 (m, 1H)
	2.20 (s, 3H)
	1.35-0.90 (m, 4H)

Example 27b2-[(4-Benzyloxy-5-methylpyrid-2-yl)methylsulphonyl]-5-chlorobenzimidazole¹H-NMR (CD₂Cl₂)

δ	8.12 (s, 1H)
	7.66 (s, 1H)
	7.61 (d, 1H)
	7.50-7.10 (m, 6H)
	6.55 (s, 1H)
	4.90-4.40 (m, 4H)
	2.12 (s, 3H)


Example 28b2-[(4-Benzyloxy-5-methylpyrid-2-yl)methylsulphonyl]-5-trifluoromethylbenzimidazole

¹H-NMR (d⁶-DMSO)

δ	8.20 (s, 1H)
	8.01 (br.s, 1H)
	7.83 (d, 1H)
	7.57 (dd, 1H)
	7.36 (s, 5H)
	6.67 (s, 1H)
	4.90-4.40 (m, 4H)
	2.18 (s, 3H)

Example 29b

2-[(4-[4-Fluorobenzyloxy]-5-methylpyrid-2-yl)methylsulphinyl]benzimidazole




¹H-NMR (CD₂Cl₂ + d⁶-DMSO)

δ	8.21 (s, 1H)
	7.80-7.55 (m, 2H)
	7.45-6.90 (m, 6H)
	6.45 (s, 1H)
	4.80-4.30 (m, 4H)
	2.15 (s, 3H)


Example 30b

2-[(4-[4-Fluorobenzyloxy]-5-methylpyrid-2-yl)methyl-
sulphinyl]-5-methylbenzimidazole



¹H-NMR (CD₂Cl₂)

δ	8.12 (s, 1H)
	7.70-6.90 (m, 7H)
	6.40 (s, 1H)
	4.80-4.20 (m, 4H)
	2.44 (s, 3H)
	2.10 (s, 3H)

Exempl 31b2-[(4-Benzyloxy-5-methylpyrid-2-yl)methylsulphinyl]-5-methylbenzimidazole¹H-NMR (CD₂Cl₂)

δ	8.13 (s, 1H)
	7.60-7.00 (m, 8H)
	6.45 (s, 1H)
	4.80-4.25 (m, 4H)
	2.44 (s, 3H)
	2.10 (s, 3H)

PHARMACOLOGY

The ability of the compounds of the invention to modify the pH of gastric acid secretion was investigated as follows:

The perfused rat stomach preparation

The modified (1) perfused stomach preparation (2) of the urethane (25% solution) anaesthetised rat, maintained at 37°C, allows the continuous measurement of pH during basal and stimulated acid secretion.

The lumen of the stomach of male Wistar rats (approximately 200 g bodyweight) was perfused, via a cannula designed to reduce the dead space of the stomach, with 5% glucose solution (37°C) at the rate of 3 ml/min. The perfusate was forced over the surface of the secretory mucosa only, the antrum being excluded. The effluent then passed over a microflow type glass pH electrode via collecting funnel situated in the non-glandular forestomach.

The secretagogue histamine was administered as a constant intravenous infusion to produce a steady rate of acid secretion. Test compounds were administered in solution as bolus intravenous injections and any effect on the pH of the perfusate noted. The perfusate pH was recorded on a potentiometric recorder and anti-secretory responses were measured in terms of the maximal reduction in hydrogen-ion concentration expressed as a percentage of the 'control' concentrations.

R sults

Perfused rat preparation:


<u>Compounds</u>	<u>dose</u>	<u>Inhibition</u>
1.b	0.5 μ mol/kg	82%
7.b	2	86%
8.b	2	80%
10.b	1	80%
18.b	2	100%
20.b	2	72%
21.b	2	100%
24.b	2.5	91%

References

1. Parsons, M.E. (1970).
Ph. D. Thesis, University of London.
2. Ghosh, M.N. and Schild, H.O. (1958).
Br. J. Pharmacol., 13, 54-61.

Claims

1. A compound of formula (I):



or a pharmaceutically acceptable salt, a quaternised derivative or a pharmaceutically acceptable solvent thereof;

wherein:

Y forms an optionally substituted phenyl ring;

n is zero or one;

R₁ is H, C₁₋₆ alkanoyl, C₁₋₆ alkanesulphonyl, or optionally substituted arylsulphonyl, aryl C₁₋₆ alkanoyl or aryl C₁₋₄ alkyl;

R₂ is hydrogen or C₁₋₄ alkyl; and

R₃ is pyridyl group substituted by at least one group selected from OR₄ or O(CH₂)_mOR₄ wherein R₄ is an optionally substituted aryl or aralkyl group of up to

- 2 -


10 carbon atoms and m is an integer of from 1 to 4; and by up to three further substituents one of which may be joined to R₂ to form a carbocyclic ring of up to 7 ring atoms.

2. A compound according to claim 1 wherein R₃ is 2-pyridyl.

3. A compound according to claim 1 or 2 wherein R₃ is further substituted by one or two of halogen C₁₋₆ alkoxy, carboxy esterified carboxy, or amino optionally N²-substituted by one or two groups independently selected from C₁₋₆ alkyl, phenyl or phenyl C₁₋₄ alkyl or optionally N,N-disubstituted by C₄₋₅ polymethylene or C₃₋₄ polymethylenecarbonyl.

4. A compound according to any one of claims 1 to 3 wherein Y is unsubstituted or includes one or two substituents selected from halo, C₁₋₆ alkyl, halo substituted C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₁₀ carboxylic acyl, C₁₋₇ carboxylic acylamino, carboxy, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulphonylamino, N-(C₁₋₆ alkylsulphonyl)-C₁₋₄ alkylamino, cyano, nitro, or amino, amido or sulphonylamino any of which is optionally N-substituted by one or two groups selected from C₁₋₆ alkyl or phenyl or optionally N-disubstituted by C₄₋₅ polymethylene; or phenyl optionally substituted by one or two substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₇ carboxylic acyl, C₁₋₇ carboxylic acylamino, C₁₋₆ alkylsulphonylamino, N-(C₁₋₆ alkylsulphonyl)-C₁₋₄ alkylamino, cyano, or nitro, amino optionally N-substituted by one or two groups selected from C₁₋₆ alkyl or phenyl or optionally N-disubstituted by C₄₋₅ polymethylene, or carboxy or C₁₋₆ alkoxycarbonyl.

5. A compound according to claim 1 of formula (II):



or a pharmaceutically acceptable salt, a quaternised derivative or a pharmaceutically acceptable solvate thereof;

wherein R_1 , R_2 and n are as hereinbefore defined in claim 1;

R_5 and R_6 are independently hydrogen or a group selected from the substituents for Y defined in claim 1;

R_8 is a group selected from OR_4 or $-O(CH_2)_m-O-R_4$; R_9 and R_{10} are independently selected from hydrogen, $-OR_4$, $-O(CH_2)_mR_4$, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkoxy, carboxy, esterified carboxy, or amino optionally substituted by one or two groups independently selected from C_{1-6} alkyl-phenyl, or phenyl- C_{1-4} alkyl or optionally N,N -disubstituted by C_{4-5} polymethylene or C_{3-4} polymethylenecarbonyl; and R_7 is a group defined above for R_{10} and R_9 or together with R_2 form C_{2-9} alkylene; wherein R_4 and m are as defined in claim 1.

6. A compound according to claim 5 wherein R_5 and R_6 are independently hydrogen, chloro, bromo, methyl, trifluoromethyl, amino or methoxy.

- 4 -


7. A compound according to claim 5 or 6 wherein R₁ is hydrogen.
8. A compound according to any one of claims 5, 6 or 7 wherein R₂ is hydrogen.
9. A compound according to any one of claims 5 to 8 wherein R₇, R₉ and R₁₀ are selected from hydrogen and C₁₋₄ alkyl.
10. A compound according to any one of claims 1 to 9 wherein R₄ is phenyl C₁₋₄ alkyl optionally substituted in the phenyl ring by one or two of halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, cyano or nitro.
11. 2-[(4-Fluorobenzyloxy)-3-methylpyrid-2-yl)methylthio]benzimidazole or 2-[(4-fluorobenzyloxy)-3-methylpyrid-2-yl)methylsulphinyl]benzimidazole.
12. A process for the preparation of a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt, a quaternised derivative or a pharmaceutically acceptable solvate thereof, which process comprises reacting a compound of formula (III) or an acid addition salt thereof:

R₃ - R₁₁

(III)

- 5 -

wherein R_3 is as defined in claim 1, with a compound of formula (IV):



wherein R_1 and Y are as defined in claim 1; and

- a) R_{11} is a group displaceable by a nucleophile; and R_{12} is CH_3SO ;
- b) R_{11} is CHR_2Q_1 where R_2 is as defined in claim 1, and Q_1 is a group displaceable by a nucleophile; and R_{12} is HS ; or
- c) R_{11} is CHR_2SH where R_2 is as defined in claim 1; and R_{12} is a group displaceable by a nucleophile;

thereafter if desired carrying out one or more of the following steps;

- (i) oxidising a compound of formula (I) wherein n is zero to a compound of formula (I) wherein n is one;
- (ii) converting any variable group to another corresponding variable R group; and

- 6 -

(iii) salifying or quaternising the resulting compound of the formula (I).

13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, a pharmaceutically acceptable salt, quaternised derivative or a pharmaceutically acceptable solvate thereof, together with a pharmaceutically acceptable carrier.

14. A compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt, quaternised derivative or a pharmaceutically acceptable solvate for use in the treatment or prophylaxis of disorders caused or exacerbated by excess gastric acid secretion.